DBV Technologies Q3 2025 Financial Results

DBV Technologies S.A. reported its financial results for the third quarter of 2025, ending September 30, 2025. The company announced a net loss of $102.1 million for the nine months ended September 30, 2025, compared to a net loss of $90.9 million for the same period in 2024. The net loss per share was $0.82 for the nine months ended September 30, 2025. The company's cash and cash equivalents stood at $69.8 million as of September 30, 2025, an increase from $32.5 million at the end of 2024. DBV Technologies expects its cash runway to extend into the third quarter of 2026. The company is actively pursuing financing options, including additional sales under its ATM Program, potential warrant exercises, and strategic transactions. DBV Technologies is focused on developing its VIASKIN® patch technology for food allergies, with ongoing clinical trials for peanut allergic toddlers and children.